<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01165229</url>
  </required_header>
  <id_info>
    <org_study_id>113077</org_study_id>
    <secondary_id>2009-015791-94</secondary_id>
    <nct_id>NCT01165229</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older</brief_title>
  <official_title>Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 70 Years or Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this observer-blind study is to evaluate the efficacy, safety and
      immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70
      years.

      Two studies (Zoster-006 [NCT01165177] and Zoster-022 [NCT01165229]) will be conducted
      concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both
      studies combined will be conducted contingent on each study achieving its objectives. This
      protocol posting also deals with the outcome measures related to the pooled analysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol summary has been updated following Protocol Amendment 4 changes to study
      objectives and endpoints. Pooled analyses of ZOSTER-006 (NCT01165177) and ZOSTER-022
      (NCT01165229) will only be conducted if the primary objective herpes zoster vaccine efficacy
      (HZ VE) is demonstrated in both ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229)
      separately.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2, 2010</start_date>
  <completion_date type="Actual">July 24, 2015</completion_date>
  <primary_completion_date type="Actual">July 24, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Any Episodes of Herpes Zoster (HZ)</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Post-herpetic Neuralgia (PHN)</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>PHN cases in the mTVc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Severe 'Worst' HZ-associated Pain</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Overall Mortality and HZ-related Mortality</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Incidence of overall and HZ-related mortality during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Confirmed HZ Episode Related Hospitalizations</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Incidence of overall and HZ-related hospitalizations during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With HZ Related Complications</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Incidence of HZ complications during the study in subjects with confirmed HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Receiving Pain Medication Associated With HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Pain Medication Associated With HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited Local Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
    <description>Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Solicited General Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within the 30 days (Days 0-29) after each vaccination</time_frame>
    <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any, Related and Fatal Serious Adverse Events (SAEs)</measure>
    <time_frame>From Month 0 to Month 14 and until study end (3 to 5 year period following Day 0)</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Potential Immune Mediated Diseases (pIMDs)</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Medically Attended Events (MAEs)</measure>
    <time_frame>From Month 0 to Month 8 post-vaccination</time_frame>
    <description>Occurrence and relationship to vaccination of medically attended visitsother than routine health care visits, from Month 0 to Month 8 in all subjects. MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Occurrence of PHN during the entire study period in all subjects with confirmed HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>The duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
    <description>Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</measure>
    <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
    <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Unsolicited AEs in Subjects ≥ 70 YOA</measure>
    <time_frame>Within 30 days (Days 0 - 29) after each vaccination</time_frame>
    <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Related and Fatal SAEs</measure>
    <time_frame>From Month 0 to Month 14 and until study end (3 to 5 year period following Day 0)</time_frame>
    <description>Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any pIMDs</measure>
    <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
    <description>Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Medically Attended Events (MAEs)</measure>
    <time_frame>From Month 0 to Month 8 post-vaccination</time_frame>
    <description>Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14819</enrollment>
  <condition>Herpes Zoster</condition>
  <arm_group>
    <arm_group_label>Zoster vaccine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive NaCl solution placebo according to a 0, 2-month schedule</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Herpes Zoster Vaccine GSK1437173A</intervention_name>
    <description>Intramuscular injection</description>
    <arm_group_label>Zoster vaccine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular injection.</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who the investigator believes will comply with the requirements of the
             protocol.

          -  Written informed consent obtained from the subject.

          -  A male or female aged 70 years or older at the time of the first vaccination.

        Exclusion Criteria:

          -  Use of any investigational or non-registered product other than the study vaccine
             within 30 days preceding the first dose of study vaccine, or planned use during the
             study period.

          -  Concurrently participating in another clinical study, at any time during the study
             period, in which the subject has been or will be exposed to an investigational or a
             non-investigational product.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition resulting
             from disease or immunosuppressive/cytotoxic therapy History of HZ.

          -  Previous vaccination against varicella or HZ.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             the vaccine. Additionally, consider allergic reactions to other material or equipment
             related to study participation.

          -  Significant underlying illness that in the opinion of the investigator would be
             expected to prevent completion of the study.

          -  Receipt of immunoglobulins and/or any blood products within the 90 days preceding the
             first dose of study vaccine or planned administration during the study period.

          -  Administration or planned administration of any other immunizations within 30 days
             before the first or second study vaccination or scheduled within 30 days after study
             vaccination. However, licensed non-replicating vaccines may be administered up to 8
             days prior to each dose and/or at least 14 days after any dose of study vaccine.

          -  Any other condition that, in the opinion of the investigator, might interfere with the
             evaluations required by the study.

          -  Acute disease and/or fever at the time of enrolment.

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85050</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Spring Valley</city>
        <state>California</state>
        <zip>91978</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vista</city>
        <state>California</state>
        <zip>92083</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33409</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <zip>21045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <zip>44281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleasant Hills</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uniontown</city>
        <state>Pennsylvania</state>
        <zip>15401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <zip>29650</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <zip>37620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Winchester</city>
        <state>Virginia</state>
        <zip>22601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glebe</city>
        <state>New South Wales</state>
        <zip>2037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maroubra</city>
        <state>New South Wales</state>
        <zip>2035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umina</city>
        <state>New South Wales</state>
        <zip>2257</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2522</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caboolture</city>
        <state>Queensland</state>
        <zip>4510</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kippa Ring</city>
        <state>Queensland</state>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivanhoe</city>
        <state>Victoria</state>
        <zip>3079</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba/Paraná</city>
        <state>Paraná</state>
        <zip>80810-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035003</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Curitiba/PR</city>
        <zip>80240-280</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04038 002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <zip>04312903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bay Roberts</city>
        <state>Newfoundland and Labrador</state>
        <zip>A0A 1G0</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4S 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9W 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woodstock</city>
        <state>Ontario</state>
        <zip>N4S 5P5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>J8Y 6S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 4S3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1E 7G9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 2G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trois Rivières</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>662 10</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 04</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13619</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <zip>50106</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02230</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jarvenpaa</city>
        <zip>04400</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kokkola</city>
        <zip>67100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cherbourg</city>
        <zip>50100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Château Gontier</city>
        <zip>53200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laval</city>
        <zip>53100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montrevault</city>
        <zip>49110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muret</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rosiers d'Egletons</city>
        <zip>19300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Cyr Sur Loir</city>
        <zip>37540</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Segré</city>
        <zip>49500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Soulaines sur Aubance</city>
        <zip>49610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tours</city>
        <zip>37100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Deggingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gueglingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74363</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mannheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wangen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69469</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dachau</city>
        <state>Bayern</state>
        <zip>85221</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuenzing</city>
        <state>Bayern</state>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rednitzhembach</city>
        <state>Bayern</state>
        <zip>91126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wallerfing</city>
        <state>Bayern</state>
        <zip>94574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Floersheim</city>
        <state>Hessen</state>
        <zip>65439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Duelmen</city>
        <state>Niedersachsen</state>
        <zip>48249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45359</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Goch</city>
        <state>Nordrhein-Westfalen</state>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Witten</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58455</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <zip>55624</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koethen</city>
        <state>Sachsen-Anhalt</state>
        <zip>06366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39112</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiberg</city>
        <state>Sachsen</state>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04315</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pirna</city>
        <state>Sachsen</state>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Luebeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23554</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10717</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22415</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kwun Tong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chieti</city>
        <state>Abruzzo</state>
        <zip>66013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pescara</city>
        <state>Abruzzo</state>
        <zip>65100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00163</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monza</city>
        <state>Lombardia</state>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuneo</city>
        <state>Piemonte</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Catania</city>
        <state>Sicilia</state>
        <zip>95129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ragusa (RG)</city>
        <state>Sicilia</state>
        <zip>97100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>810-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>813-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>816-0864</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>224-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>247-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>611-0041</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>141-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>154-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ansan</city>
        <zip>425-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucheon-si,</city>
        <zip>420-767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>400-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangnam-gu, Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kangwon-do</city>
        <zip>220-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>150-950</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zapopan, Jalisco</city>
        <state>Jalisco</state>
        <zip>45190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>62210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alcover( Tarragona)</city>
        <zip>43460</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Balenyà (Barcelona)</city>
        <zip>08550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Roca Del Valles (Barcelona)</city>
        <zip>08430</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Peralada( Girona)</city>
        <zip>17491</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46020</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vic/ Barcelona</city>
        <zip>08500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Borås</city>
        <zip>SE-506 30</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eskilstuna</city>
        <zip>SE-631 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jönköping</city>
        <zip>SE-551 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-58758</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>SE-211 52</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skövde</city>
        <zip>SE-541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-111 57</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vällingby</city>
        <zip>SE-162 68</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-703 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Buckshaw Village, Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atherstone</city>
        <state>Warwickshire</state>
        <zip>CV9 1EU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <state>Wiltshire</state>
        <zip>BA15 1DQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangor</city>
        <zip>BT19 1PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT7 2EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Broughshane</city>
        <zip>BT42 4JP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ledbury</city>
        <zip>HR8 2AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newtonabbey</city>
        <zip>BT37 9QW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo, Liverpool</city>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2010</study_first_submitted>
  <study_first_submitted_qc>July 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2010</study_first_posted>
  <results_first_submitted>May 9, 2017</results_first_submitted>
  <results_first_submitted_qc>November 10, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 20, 2017</results_first_posted>
  <disposition_first_submitted>August 22, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 22, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 30, 2013</disposition_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunogenicity</keyword>
  <keyword>Subjects 70 years and older</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Herpes Zoster</keyword>
  <keyword>Safety</keyword>
  <keyword>Adults</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of the 14819 subjects originally enrolled in the study, only 13900 subjects have been vaccinated and included in the Total Vaccinated Cohort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Zoster-022 GSK1437173A Group</title>
          <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="P2">
          <title>Zoster-022 Placebo Group</title>
          <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6950"/>
                <participants group_id="P2" count="6950"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5770"/>
                <participants group_id="P2" count="5761"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1180"/>
                <participants group_id="P2" count="1189"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unknown completion status</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="459"/>
                <participants group_id="P2" count="487"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="396"/>
                <participants group_id="P2" count="403"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Migrated/moved from study area</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
                <participants group_id="P2" count="138"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Suspected HZ Episode</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No reason from the subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Page entered in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient not eligible</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Health issues</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closure</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reason</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor study termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed visit</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of time</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Screening criteria unmet</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zoster-022 GSK1437173A Group</title>
          <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="B2">
          <title>Zoster-022 Placebo Group</title>
          <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6950"/>
            <count group_id="B2" value="6950"/>
            <count group_id="B3" value="13900"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.6" spread="4.7"/>
                    <measurement group_id="B2" value="75.6" spread="4.7"/>
                    <measurement group_id="B3" value="75.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3789"/>
                    <measurement group_id="B2" value="3836"/>
                    <measurement group_id="B3" value="7625"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3161"/>
                    <measurement group_id="B2" value="3114"/>
                    <measurement group_id="B3" value="6275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Geographic ancestry</title>
              <category_list>
                <category>
                  <title>African Heritage / African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaskan Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - Central/South Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="907"/>
                    <measurement group_id="B2" value="908"/>
                    <measurement group_id="B3" value="1815"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - Japanese Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="298"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="598"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian - South East Asian Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Arabic / North African Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White - Caucasian / European Heritage</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5307"/>
                    <measurement group_id="B2" value="5301"/>
                    <measurement group_id="B3" value="10608"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="306"/>
                    <measurement group_id="B3" value="610"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Any Episodes of Herpes Zoster (HZ)</title>
        <description>Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Episodes of Herpes Zoster (HZ)</title>
          <description>Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5114"/>
                <count group_id="O2" value="1427"/>
                <count group_id="O3" value="6541"/>
                <count group_id="O4" value="5189"/>
                <count group_id="O5" value="1433"/>
                <count group_id="O6" value="6622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="169"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>90.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>83.54</ci_lower_limit>
            <ci_upper_limit>94.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>89.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>74.65</ci_lower_limit>
            <ci_upper_limit>96.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>89.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.29</ci_lower_limit>
            <ci_upper_limit>93.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)</title>
        <description>Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022/006 Pooled Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022/006 Pooled Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022/006 Pooled Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)</title>
          <description>Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6468"/>
                <count group_id="O2" value="1782"/>
                <count group_id="O3" value="8250"/>
                <count group_id="O4" value="6554"/>
                <count group_id="O5" value="1792"/>
                <count group_id="O6" value="8346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="7"/>
                    <measurement group_id="O6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>93.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.47</ci_lower_limit>
            <ci_upper_limit>99.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1844</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>71.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-51.51</ci_lower_limit>
            <ci_upper_limit>97.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>88.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>68.70</ci_lower_limit>
            <ci_upper_limit>97.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ</title>
        <description>Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022/006 Pooled Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022/006 Pooled Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022/006 Pooled Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ</title>
          <description>Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6468"/>
                <count group_id="O2" value="1782"/>
                <count group_id="O3" value="8250"/>
                <count group_id="O4" value="6554"/>
                <count group_id="O5" value="1792"/>
                <count group_id="O6" value="8346"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="216"/>
                    <measurement group_id="O5" value="68"/>
                    <measurement group_id="O6" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>91.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.04</ci_lower_limit>
            <ci_upper_limit>94.85</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>91.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>80.22</ci_lower_limit>
            <ci_upper_limit>96.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Poisson</method>
            <param_type>1-RR</param_type>
            <param_value>91.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.88</ci_lower_limit>
            <ci_upper_limit>94.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Post-herpetic Neuralgia (PHN)</title>
        <description>PHN cases in the mTVc.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Post-herpetic Neuralgia (PHN)</title>
          <description>PHN cases in the mTVc.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5114"/>
                <count group_id="O2" value="1427"/>
                <count group_id="O3" value="6541"/>
                <count group_id="O4" value="5189"/>
                <count group_id="O5" value="1433"/>
                <count group_id="O6" value="6622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="22"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Severe ‘Worst’ HZ-associated Pain</title>
        <description>Duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Severe ‘Worst’ HZ-associated Pain</title>
          <description>Duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="150"/>
                <count group_id="O5" value="48"/>
                <count group_id="O6" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8" spread="31.41"/>
                    <measurement group_id="O2" value="98.7" spread="57.73"/>
                    <measurement group_id="O3" value="34.6" spread="45.54"/>
                    <measurement group_id="O4" value="47.9" spread="100.08"/>
                    <measurement group_id="O5" value="50.4" spread="106.51"/>
                    <measurement group_id="O6" value="48.5" spread="101.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations</title>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations</title>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5114"/>
                <count group_id="O2" value="1427"/>
                <count group_id="O3" value="6541"/>
                <count group_id="O4" value="5189"/>
                <count group_id="O5" value="1433"/>
                <count group_id="O6" value="6622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mortality or hospitalization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Overall Mortality and HZ-related Mortality</title>
        <description>Incidence of overall and HZ-related mortality during the study.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Overall Mortality and HZ-related Mortality</title>
          <description>Incidence of overall and HZ-related mortality during the study.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5114"/>
                <count group_id="O2" value="1427"/>
                <count group_id="O3" value="6541"/>
                <count group_id="O4" value="5189"/>
                <count group_id="O5" value="1433"/>
                <count group_id="O6" value="6622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Confirmed HZ Episode Related Hospitalizations</title>
        <description>Incidence of overall and HZ-related hospitalizations during the study.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Confirmed HZ Episode Related Hospitalizations</title>
          <description>Incidence of overall and HZ-related hospitalizations during the study.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5114"/>
                <count group_id="O2" value="1427"/>
                <count group_id="O3" value="6541"/>
                <count group_id="O4" value="5189"/>
                <count group_id="O5" value="1433"/>
                <count group_id="O6" value="6622"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With HZ Related Complications</title>
        <description>Incidence of HZ complications during the study in subjects with confirmed HZ.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With HZ Related Complications</title>
          <description>Incidence of HZ complications during the study in subjects with confirmed HZ.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="169"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least one complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HZ vasculitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Disseminated Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ophthalmic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visceral Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Receiving Pain Medication Associated With HZ</title>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Receiving Pain Medication Associated With HZ</title>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="23"/>
                <count group_id="O4" value="169"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At least 1 pain medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="123"/>
                    <measurement group_id="O5" value="37"/>
                    <measurement group_id="O6" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 pain medication only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 pain medications only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 pain medications or more</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="50"/>
                    <measurement group_id="O5" value="16"/>
                    <measurement group_id="O6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Pain Medication Associated With HZ</title>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 GSK1437173A &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022 GSK1437173A &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022 Placebo 70-79YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022 Placebo &gt;=80YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022 Placebo &gt;=70YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Pain Medication Associated With HZ</title>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="56.44"/>
                    <measurement group_id="O2" value="274.7" spread="337.00"/>
                    <measurement group_id="O3" value="109.5" spread="200.88"/>
                    <measurement group_id="O4" value="218.6" spread="593.80"/>
                    <measurement group_id="O5" value="135.0" spread="207.31"/>
                    <measurement group_id="O6" value="199.3" spread="530.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited Local Symptoms</title>
        <description>Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
        <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited Local Symptoms</title>
          <description>Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
          <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="505"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="502"/>
                    <count group_id="O2" value="504"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="297"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="502"/>
                    <count group_id="O2" value="504"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="502"/>
                    <count group_id="O2" value="504"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="502"/>
                    <count group_id="O2" value="504"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="502"/>
                    <count group_id="O2" value="504"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="502"/>
                    <count group_id="O2" value="504"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="282"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="491"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="505"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="505"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="505"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="198"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="505"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="505"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="505"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="504"/>
                <count group_id="O2" value="505"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastrointestinal, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastrointestinal, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="501"/>
                    <count group_id="O2" value="503"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                    <measurement group_id="O2" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastrointestinal, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastrointestinal, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="492"/>
                    <count group_id="O2" value="489"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastrointestinal, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastrointestinal, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="504"/>
                    <count group_id="O2" value="505"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
        <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 30 days (Days 0-29) after each vaccination</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Unsolicited Adverse Events (AEs)</title>
          <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6950"/>
                <count group_id="O2" value="6950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3859"/>
                    <measurement group_id="O2" value="2263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="485"/>
                    <measurement group_id="O2" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2853"/>
                    <measurement group_id="O2" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any, Related and Fatal Serious Adverse Events (SAEs)</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>From Month 0 to Month 14 and until study end (3 to 5 year period following Day 0)</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any, Related and Fatal Serious Adverse Events (SAEs)</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6950"/>
                <count group_id="O2" value="6695"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s) up to Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="891"/>
                    <measurement group_id="O2" value="939"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s) up to Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAE(s) up to Month 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE(s) up to study end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1153"/>
                    <measurement group_id="O2" value="1214"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s) up to study end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAE(s) up to study end</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="426"/>
                    <measurement group_id="O2" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Potential Immune Mediated Diseases (pIMDs)</title>
        <description>Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Potential Immune Mediated Diseases (pIMDs)</title>
          <description>Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6950"/>
                <count group_id="O2" value="6950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Medically Attended Events (MAEs)</title>
        <description>Occurrence and relationship to vaccination of medically attended visitsother than routine health care visits, from Month 0 to Month 8 in all subjects. MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.</description>
        <time_frame>From Month 0 to Month 8 post-vaccination</time_frame>
        <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022 GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022 Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Medically Attended Events (MAEs)</title>
          <description>Occurrence and relationship to vaccination of medically attended visitsother than routine health care visits, from Month 0 to Month 8 in all subjects. MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.</description>
          <population>This analysis was based on the the total vaccinated cohort, which included all subjects with at least one dose of study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6950"/>
                <count group_id="O2" value="6950"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2882"/>
                    <measurement group_id="O2" value="2911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA</title>
        <description>Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group</title>
            <description>Subjects between 50 and 59 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group</title>
            <description>Subjects between 60 and 69 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=50 YOA Group</title>
            <description>Subjects above 50 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022/006 Pooled Placebo 50-59 YOA Group</title>
            <description>Subjects between 50 and 59 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Zoster-022/006 Pooled Placebo 60-69 YOA Group</title>
            <description>Subjects between 60 and 69 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Zoster-022/006 Pooled Placebo 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Zoster-022/006 Pooled Placebo &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O10">
            <title>Zoster-022/006 Pooled Placebo &gt;=50 YOA Group</title>
            <description>Subjects above 50 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA</title>
          <description>Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3491"/>
                <count group_id="O2" value="2140"/>
                <count group_id="O3" value="6468"/>
                <count group_id="O4" value="1782"/>
                <count group_id="O5" value="13881"/>
                <count group_id="O6" value="3523"/>
                <count group_id="O7" value="2166"/>
                <count group_id="O8" value="6554"/>
                <count group_id="O9" value="1792"/>
                <count group_id="O10" value="14035"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="29"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ</title>
        <description>Occurrence of PHN during the entire study period in all subjects with confirmed HZ.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group</title>
            <description>Subjects between 50 and 59 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group</title>
            <description>Subjects between 60 and 69 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=50 YOA Group</title>
            <description>Subjects above 50 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022/006 Pooled Placebo 50-59 YOA Group</title>
            <description>Subjects between 50 and 59 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O7">
            <title>Zoster-022/006 Pooled Placebo 60-69 YOA Group</title>
            <description>Subjects between 60 and 69 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O8">
            <title>Zoster-022/006 Pooled Placebo 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O9">
            <title>Zoster-022/006 Pooled Placebo &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O10">
            <title>Zoster-022/006 Pooled Placebo &gt;=50 YOA Group</title>
            <description>Subjects above 50 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ</title>
          <description>Occurrence of PHN during the entire study period in all subjects with confirmed HZ.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="103"/>
                <count group_id="O7" value="90"/>
                <count group_id="O8" value="216"/>
                <count group_id="O9" value="68"/>
                <count group_id="O10" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="8"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="29"/>
                    <measurement group_id="O9" value="7"/>
                    <measurement group_id="O10" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe ‘Worst’ HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.</title>
        <description>The duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=70 YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022/006 Pooled Placebo 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022/006 Pooled Placebo &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022/006 Pooled Placebo &gt;=70 YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe ‘Worst’ HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.</title>
          <description>The duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="216"/>
                <count group_id="O5" value="68"/>
                <count group_id="O6" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="193"/>
                    <measurement group_id="O5" value="61"/>
                    <measurement group_id="O6" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe ‘Worst’ HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.</title>
        <description>Duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O3">
            <title>Zoster-022/006 Pooled GSK1437173A &gt;=70 YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O4">
            <title>Zoster-022/006 Pooled Placebo 70-79 YOA Group</title>
            <description>Subjects between 70 and 79 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O5">
            <title>Zoster-022/006 Pooled Placebo &gt;=80 YOA Group</title>
            <description>Subjects above 80 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O6">
            <title>Zoster-022/006 Pooled Placebo &gt;=70 YOA Group</title>
            <description>Subjects above 70 years of age (YOA), receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe ‘Worst’ HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.</title>
          <description>Duration of severe ‘worst’ HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.</description>
          <population>The analysis was based on the modified total vaccinated cohort, which included subjects from the total vaccinated cohort, except those who were not administered with the second vaccination or who developed a confirmed case of Herpes Zoster prior to 1 month after the second vaccination.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="193"/>
                <count group_id="O5" value="61"/>
                <count group_id="O6" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.3" spread="29.71"/>
                    <measurement group_id="O2" value="98.7" spread="57.73"/>
                    <measurement group_id="O3" value="32.1" spread="43.80"/>
                    <measurement group_id="O4" value="48.3" spread="96.34"/>
                    <measurement group_id="O5" value="45.2" spread="95.58"/>
                    <measurement group_id="O6" value="47.5" spread="95.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
        <description>Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
        <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms</title>
          <description>Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.</description>
          <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2258"/>
                <count group_id="O2" value="2263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2246"/>
                    <count group_id="O2" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1336"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2246"/>
                    <count group_id="O2" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2246"/>
                    <count group_id="O2" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2246"/>
                    <count group_id="O2" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2246"/>
                    <count group_id="O2" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2246"/>
                    <count group_id="O2" value="2255"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2160"/>
                    <count group_id="O2" value="2169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1241"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2160"/>
                    <count group_id="O2" value="2169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2160"/>
                    <count group_id="O2" value="2169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="582"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2160"/>
                    <count group_id="O2" value="2169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2160"/>
                    <count group_id="O2" value="2169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="344"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2160"/>
                    <count group_id="O2" value="2169"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2258"/>
                    <count group_id="O2" value="2263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1562"/>
                    <measurement group_id="O2" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2258"/>
                    <count group_id="O2" value="2263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2258"/>
                    <count group_id="O2" value="2263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="851"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2258"/>
                    <count group_id="O2" value="2263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2258"/>
                    <count group_id="O2" value="2263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="519"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2258"/>
                    <count group_id="O2" value="2263"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
        <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses</time_frame>
        <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms</title>
          <description>Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever [defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever &gt; 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was performed on the total vaccinated cohort – Diary Card, which was a subset of subjects from the total vaccinated cohort, who completed diary cards with any solicited symptoms during the 7 days (Day 0 to Day 6) post vaccination period.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2252"/>
                <count group_id="O2" value="2264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545"/>
                    <measurement group_id="O2" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastrointestinal, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastrointestinal, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="189"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293"/>
                    <measurement group_id="O2" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="530"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="445"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2237"/>
                    <count group_id="O2" value="2256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="579"/>
                    <measurement group_id="O2" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="495"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastrointestinal, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastrointestinal, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="455"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="560"/>
                    <measurement group_id="O2" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="484"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2159"/>
                    <count group_id="O2" value="2166"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Fatigue, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="825"/>
                    <measurement group_id="O2" value="326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Fatigue, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fatigue, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="699"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Gastrointestinal, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="304"/>
                    <measurement group_id="O2" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Gastrointestinal,Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Gastrointestinal,Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Headache, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Headache, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Headache, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="547"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Myalgia, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="790"/>
                    <measurement group_id="O2" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Myalgia, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Myalgia, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="689"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Shivering, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Shivering, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Shivering, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Temperature, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Temperature, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Temperature, Across Doses</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2252"/>
                    <count group_id="O2" value="2264"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Unsolicited AEs in Subjects ≥ 70 YOA</title>
        <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
        <time_frame>Within 30 days (Days 0 - 29) after each vaccination</time_frame>
        <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Unsolicited AEs in Subjects ≥ 70 YOA</title>
          <description>Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.</description>
          <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8758"/>
                <count group_id="O2" value="8773"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4366"/>
                    <measurement group_id="O2" value="2732"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="553"/>
                    <measurement group_id="O2" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2961"/>
                    <measurement group_id="O2" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Related and Fatal SAEs</title>
        <description>Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA.</description>
        <time_frame>From Month 0 to Month 14 and until study end (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Related and Fatal SAEs</title>
          <description>Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA.</description>
          <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8758"/>
                <count group_id="O2" value="8773"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1117"/>
                    <measurement group_id="O2" value="1171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal SAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any pIMDs</title>
        <description>Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.</description>
        <time_frame>During the entire study period (3 to 5 year period following Day 0)</time_frame>
        <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any pIMDs</title>
          <description>Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.</description>
          <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8758"/>
                <count group_id="O2" value="8773"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related pIMD(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Medically Attended Events (MAEs)</title>
        <description>Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.</description>
        <time_frame>From Month 0 to Month 8 post-vaccination</time_frame>
        <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
        <group_list>
          <group group_id="O1">
            <title>Zoster-022/006 Pooled GSK1437173A Group</title>
            <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
          </group>
          <group group_id="O2">
            <title>Zoster-022/006 Pooled Placebo Group</title>
            <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Medically Attended Events (MAEs)</title>
          <description>Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.</description>
          <population>The analysis was based on the total vaccinated cohort, which included all vaccinated subjects with study vaccine or placebo administered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8758"/>
                <count group_id="O2" value="8773"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3593"/>
                    <measurement group_id="O2" value="3648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related MAE(s)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Zoster-022 GSK1437173A Group</title>
          <description>Subjects receiving herpes zoster subunit vaccine (gE/AS01B vaccine) according to a 0, 2-month schedule.</description>
        </group>
        <group group_id="E2">
          <title>Zoster-022 Placebo Group</title>
          <description>Subjects receiving saline solution (NaCl solution) as control according to a 0, 2-month schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="426" subjects_at_risk="6950"/>
                <counts group_id="E2" subjects_affected="459" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1153" subjects_at_risk="6950"/>
                <counts group_id="E2" subjects_affected="1214" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anaemia vitamin b12 deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Disseminated intravascular coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypersplenism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nephrogenic anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="6950"/>
                <counts group_id="E2" events="29" subjects_affected="28" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="45" subjects_affected="40" subjects_at_risk="6950"/>
                <counts group_id="E2" events="56" subjects_affected="54" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="6950"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="52" subjects_affected="51" subjects_at_risk="6950"/>
                <counts group_id="E2" events="62" subjects_affected="57" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="6950"/>
                <counts group_id="E2" events="37" subjects_affected="33" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac tamponade</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chronotropic incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="6950"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coronary artery insufficiency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Heart valve incompetence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Left ventricular hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="43" subjects_affected="41" subjects_at_risk="6950"/>
                <counts group_id="E2" events="45" subjects_affected="45" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tricuspid valve incompetence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypertrophic cardiomyopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Amaurosis fugax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Choroidal effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Iridocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ocular vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Abdominal strangulated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Autoimmune pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diaphragmatic hernia, obstructive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Faecal incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastric perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastrointestinal angiodysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Incarcerated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Inguinal hernia strangulated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intestinal infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mallory-weiss syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mesenteric artery embolism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mesenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peptic ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pharyngo-oesophageal diverticulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Salivary gland calculus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thrombosis mesenteric vessel</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Administration site erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Administration site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="6950"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6950"/>
                <counts group_id="E2" events="29" subjects_affected="29" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Device deposit issue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Device leakage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Device occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6950"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Organ failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thrombosis in device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Biliary dilatation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="17" subjects_affected="15" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="6950"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chronic hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cirrhosis alcoholic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatitis alcoholic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ischaemic hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic granulomatous angiitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Amyloidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Alcaligenes infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anal fistula infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anorectal cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Candida sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cavernous sinus thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6950"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholecystitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Clostridium bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colonic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diabetic foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Enterocolitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Escherichia infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Graft infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Herpes zoster disseminated</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Herpes zoster meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Incision site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Infected dermal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intestinal gangrene</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Klebsiella bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ovarian abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatic abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="73" subjects_affected="70" subjects_at_risk="6950"/>
                <counts group_id="E2" events="86" subjects_affected="81" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia influenzal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pseudomembranous colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pseudomonas infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Psittacosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Psoas abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Respiratory moniliasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="6950"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6950"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Staphylococcal osteomyelitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="32" subjects_affected="28" subjects_at_risk="6950"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coronary artery reocclusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coronary artery restenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis postoperative</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Eye penetration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Face injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6950"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gun shot wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Kidney contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Post procedural pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Postoperative wound complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Procedural intestinal perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spinal cord injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spinal cord injury cervical</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Synovial rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Traumatic intracranial haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vascular graft occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Wound evisceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Blood glucose fluctuation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Marasmus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Uraemic acidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired claw toe</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arthrofibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cervical spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chondrocalcinosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mixed connective tissue disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="6950"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Osteochondritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Polymyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Still's disease adult onset</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acral lentiginous melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acute monocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Adrenal adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Adrenal gland cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anaplastic astrocytoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anaplastic thyroid cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>B precursor type acute leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Benign neoplasm of thyroid gland</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Benign ovarian tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bile duct cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Brain neoplasm benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour pulmonary</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Central nervous system neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cholesteatoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diffuse large b-cell lymphoma stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Fallopian tube cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastrointestinal stromal tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatic cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hepatocellular carcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypergammaglobulinaemia benign monoclonal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intestinal adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Invasive papillary breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Large cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Large intestine benign neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="6950"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malignant fibrous histiocytoma of bone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malignant lymphoma unclassifiable high grade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malignant mast cell neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of ampulla of vater</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Malignant palate neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to adrenals</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to central nervous system</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to gastrointestinal tract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to peritoneum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastases to stomach</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastatic renal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Neoplasm prostate</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Non-hodgkin's lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal adenocarcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal cancer metastatic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ovarian cancer recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ovarian epithelial cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatic neoplasm</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pancreatic neuroendocrine tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Paraganglion neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Parathyroid tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="6950"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostate cancer stage iv</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal adenoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal cancer recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Salivary gland cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Small intestine adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the oral cavity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sweat gland tumour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Throat cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage unspecified</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urethral neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vulval cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Amyotrophic lateral sclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Basilar artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Brain stem syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Carotid artery occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Central nervous system lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebellar ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebral artery embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebral artery thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebral atrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="6950"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="6950"/>
                <counts group_id="E2" events="33" subjects_affected="31" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dementia alzheimer's type</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dementia with lewy bodies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Drop attacks</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dural arteriovenous fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dyspraxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Guillain-barre syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intraventricular haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Miller fisher syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mixed dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Myasthenia gravis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Progressive supranuclear palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Senile dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Spondylitic myelopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6950"/>
                <counts group_id="E2" events="22" subjects_affected="20" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thalamus haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thrombotic cerebral infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="22" subjects_affected="20" subjects_at_risk="6950"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Viiith nerve lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Viith nerve paralysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acute psychosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Breathing-related sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mental disorder due to a general medical condition</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Panic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Schizoaffective disorder bipolar type</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Somatoform disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="6950"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder perforation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bladder prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Cystitis interstitial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nephroangiosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Neurogenic bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prerenal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="6950"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urethral meatus stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Atrophic vulvovaginitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Breast dysplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostatic obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vaginal ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="26" subjects_affected="21" subjects_at_risk="6950"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diaphragmatic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pulmonary cavitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6950"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="6950"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Dermatomyositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Stasis dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Rectal polypectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Femoral artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="6950"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Inferior vena caval occlusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Intermittent claudication</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Internal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Labile hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Microscopic polyangiitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Necrosis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6950"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6950"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Temporal arteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thromboangiitis obliterans</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6950"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3067" subjects_at_risk="6950"/>
                <counts group_id="E2" subjects_affected="610" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="415" subjects_affected="353" subjects_at_risk="6950"/>
                <counts group_id="E2" events="46" subjects_affected="39" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="592" subjects_affected="474" subjects_at_risk="6950"/>
                <counts group_id="E2" events="192" subjects_affected="169" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="1150" subjects_affected="864" subjects_at_risk="6950"/>
                <counts group_id="E2" events="29" subjects_affected="27" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2762" subjects_affected="1975" subjects_at_risk="6950"/>
                <counts group_id="E2" events="165" subjects_affected="148" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="773" subjects_affected="613" subjects_at_risk="6950"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="669" subjects_affected="428" subjects_at_risk="6950"/>
                <counts group_id="E2" events="67" subjects_affected="60" subjects_at_risk="6950"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="633" subjects_affected="535" subjects_at_risk="6950"/>
                <counts group_id="E2" events="56" subjects_affected="52" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="472" subjects_affected="378" subjects_at_risk="6950"/>
                <counts group_id="E2" events="113" subjects_affected="99" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="717" subjects_affected="586" subjects_at_risk="6950"/>
                <counts group_id="E2" events="307" subjects_affected="243" subjects_at_risk="6950"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

